Matching Items (3)
Filtering by
- Creators: Brian, Jennifer
- Creators: Glynn, Emily Sanders
- Resource Type: Text
Description
While there is extensive information available about organizations that receive donated organs for transplant, much less is known about those that accept tissue and whole bodies for medical education and research. Throughout the United States, nontransplant anatomical donation organizations exist within an ambiguous sector of the donation industry, unencumbered by federal regulations. Although these companies adhere to the Uniform Anatomical Gift Act, the lack of a single entity responsible for overseeing their operations has led to public skepticism and animosity among competing businesses. Legislation has the potential to legitimize the industry. For it to be successful, however, the intricacies of a complex market that deals directly with the movement of human remains and intangible issues of human integrity and morality, must be thoroughly understood.
ContributorsGlynn, Emily Sanders (Author) / Brian, Jennifer (Thesis director) / Fisher, Rebecca (Committee member) / Barrett, The Honors College (Contributor) / School of Nutrition and Health Promotion (Contributor) / Department of English (Contributor)
Created2015-05
Description
This thesis elucidates the responsibility of the pharmaceutical industry for the current opioid epidemic, an epidemic which caused over 40,000 American deaths in 2016 alone. Twenty years prior, Purdue Pharma unleashed an extended-release formulation of the opioid oxycodone: OxyContin. With this, Purdue began a highly aggressive advertising campaign with the primary intention of guaranteeing the success of this drug; however, in doing so, they often neglected to ensure that the information they were propagating was wholly accurate. Previous reform attempts aimed at mollifying this crisis have ultimately fallen short, as they have failed to recognize the true extent of Purdue Pharma's involvement, especially with regard to the underlying issues that led to the initiation and progression of the epidemic. Future improvements should be targeted at the reform of regulatory agencies and insurance companies, as well as the cultural attitudes regarding pain and pain treatment that have been cultivated over the last several years. Ultimately, however, these reforms will likely prove to be insufficient unless the failings of the current healthcare system, including the pharmaceutical industry, are also taken into account.
ContributorsOzeran, Rachel Hoku Lii (Author) / Fong, Benjamin (Thesis director) / Brian, Jennifer (Committee member) / School of Life Sciences (Contributor) / Barrett, The Honors College (Contributor)
Created2018-05
Description
The current American opioid crisis is seeing an exponential number of fatalities. The opioid epidemic is a problem with massive scope, and while no clear reason has been identified, many causal relationships have been linked to its genesis. This thesis examines the role of the pharmaceutical industry in perpetuating the abuse rates we see today. Topics of sociological norms and values, economic incentives that benefitted private business practices, and political-legal means of restitution and market completion are examined to make sense of specific mechanisms that the pharmaceutical industry took advantage of, and the future trajectory of what is to come from the industry as well. Combined with policies (or, lack thereof) that do not provide adequate checks against opioid marketing strategies and incentives, governmental interferences come too little, too late in attempting to solve the issue.
ContributorsHouang, Michael (Author) / Brian, Jennifer (Thesis director) / Silverman, Daniel (Committee member) / Department of Economics (Contributor) / School of Politics and Global Studies (Contributor) / W.P. Carey School of Business (Contributor) / Sanford School of Social and Family Dynamics (Contributor) / Barrett, The Honors College (Contributor)
Created2018-05